C-peptide vs BDNF
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and BDNF (Brain-Derived Neurotrophic Factor (mature BDNF)) — benefits, dosing, side effects, research data, and where to buy.
| Property | C-peptide | BDNF |
|---|---|---|
| Category | Pain Management | Cognitive Enhancement |
| Full Name | Connecting peptide (C-peptide) | Brain-Derived Neurotrophic Factor (mature BDNF) |
| Molecular Weight | 3020.3 Da | 13,700 Da |
| Half-Life | ~20-30 min | minutes to hours |
| Amino Acids | 31 | 119 aa |
| Typical Dose | no approved analgesic dose|research-only | research-only microgram range |
| Route | IV|subQ | Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 8000 |
| Research Status | Pre-clinical | Pre-clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
BDNF Benefits
- ✓neurogenesis
- ✓synaptogenesis
- ✓LTP support
- ✓neuronal survival
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
BDNF Dosing
0.1-1 µg local or intranasal research delivery|viral or protein infusion models|acute or repeated plasticity protocols
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
BDNF Side Effects
- ⚠off-target neuroexcitation
- ⚠headache-like effects
- ⚠unknown systemic protein effects
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
BDNF
BDNF is repeatedly associated with learning, long-term potentiation, and recovery from neurologic injury in preclinical literature. Direct protein delivery is difficult, so most studies focus on pathways that raise endogenous BDNF or on localized experimental administration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.